United Kingdom
Mosaic TX, established in 2020 and headquartered in the United Kingdom, is forging a path in the Biotechnology and Health and Wellness industries. Their mission, encapsulated in the slogan "Resolving cancer's complexity through the power of targeted drug combinations," highlights their focus on addressing critical unmet needs in oncology through innovative therapies.
Their strength lies in a unique dual technology platform, honed over two decades, that focuses on pioneering combination therapies for various cancer types. This platform, developed alongside the prestigious Wellcome Sanger Institute and Netherlands Cancer Institute, drives their precision medicine initiatives, particularly for patient groups lacking targeted treatment options.
Recently, Mosaic TX secured a $28.00M Series A investment as of April 1, 2023, led by investors Cambridge Innovation Capital and Syncona Investment Management. This funding underscores strong investor confidence in their novel approach to cancer treatment and promises to propel their growth within this competitive sector.
